Subscribe
Core coverageLLY

Company profile / LLY

Eli Lilly

Clinaptis stanceCautious
ConvictionMedium
Ticker
LLY
Exchange
NYSE
Coverage
Standard profile
Updated
Oct 3, 2026
Metabolic / Neuroscience / Oncology

Global pharmaceutical company anchored by the rapidly compounding Mounjaro and Zepbound franchise, with successor metabolic products spanning oral GLP-1, triple agonism and amylin combination therapy alongside growing immunology, oncology and neuroscience businesses.

01 / Clinaptis view

The current read

The core franchise is still compounding at extraordinary rates. Lilly generated $23.0B of Q2 revenue, up 48% year over year, led by Mounjaro at $9.9B, up 91%, and Zepbound at $4.9B, up 46%. Together, tirzepatide is already running at roughly a $60B annualized revenue rate. The growth is overwhelmingly volume-led: company-wide volume rose 60% while realized price fell 13%, including 37% U.S. volume growth against approximately 9% underlying price erosion. That is both the strength of the franchise and the central valuation tension.

  1. The pipeline increasingly looks capable of extending, rather than merely defending, the metabolic franchise. Foundayo has established an oral entry point and generated $98M in its first reported quarter; retatrutide has now produced five positive Phase 3 studies, including 20.8% weight loss in type 2 diabetes in TRIUMPH-2, with a U.S. obesity filing planned for Q1 2027. EloraTZP then delivered 23.3% weight loss at 48 weeks versus 14.8% for tirzepatide 15 mg in type 2 diabetes, supporting Phase 3 initiation in Q4 2026. Lilly therefore has credible products across oral convenience, high-efficacy triple agonism and amylin combination therapy behind an already dominant tirzepatide franchise.
  2. The rest of Lilly is becoming material again, but remains small relative to metabolic. Key products outside cardiometabolic are growing rapidly: Ebglyss reached $201M, up 131%; Jaypirca reached $192M, up 56%; and Kisunla reached $167M in Q2. Collectively, Lilly’s key immunology, oncology and neuroscience products grew 121%. These franchises improve diversification, but tirzepatide still dominates the earnings and valuation debate.
  3. Our negative stance is therefore valuation-led, not franchise-led. Lilly is executing close to the metabolic bull case, but the valuation requires extraordinary volume growth to persist while absorbing lower realized pricing, payer leverage, competitive entry and enormous manufacturing investment. We are constructive on the franchise and cautious on the security.
02 / Consensus gap

Where the market may differ

We disagree less on market size than on the economics of capturing it. The bull case increasingly assumes that obesity treatment expands fast enough for successive Lilly products to enlarge the franchise rather than cannibalize it. Q2 supports the demand side of that argument: 60% volume growth drove 48% revenue growth. It also exposes the offset—the same quarter carried 13% realized-price erosion, while ex-U.S. volume rose 113% against a 36% price decline.

  1. Pipeline success does not automatically translate into equivalent incremental value. Retatrutide materially raises the efficacy ceiling, Foundayo broadens access through an oral formulation, and EloraTZP could extend efficacy further. But each new product increasingly competes against Lilly’s own very successful incumbent franchise as well as Novo and subsequent entrants. The valuation question is therefore not simply the peak sales of each asset in isolation, but how much genuinely incremental patient volume, duration and pricing each generation adds to the consolidated franchise.
  2. The burden of proof has shifted from clinical execution to earnings duration. Mounjaro and Zepbound are already approaching a roughly $60B annualized run-rate, while Lilly is investing aggressively to support further expansion, including a broader $50B U.S. manufacturing program. At this scale, upside increasingly requires the category itself to keep expanding while price and mix compression remain manageable.
  3. The key disagreement is therefore not whether Lilly remains the best-positioned metabolic franchise. It is whether extraordinary franchise quality still produces attractive equity returns when the stock already capitalizes years of category expansion, pipeline conversion and successful lifecycle management.
Coverage state
Standard profile
What the review turns on
Key variable

Metabolic volume growth versus net-price compression and the incremental value of successive pipeline generations.

Next catalyst

EloraTZP · Phase 3 initiation · Q4 2026

03 / Pipeline

Key programs

8 assets · 8 programs

AssetIndicationStageNext event
Mounjaro / Zepbound (tirzepatide)
Type 2 diabetes / Obesity / OSA
Commercial
Commercial volume / price bridge$9.9B Mounjaro plus $4.9B Zepbound in Q2 2026
Foundayo (orforglipron)
Obesity / Type 2 diabetes
Commercial
Early launch execution
Retatrutide
Obesity / Type 2 diabetes
Phase 3
U.S. obesity filing · Q1 2027TRIUMPH-2 delivered 20.8% weight loss in type 2 diabetes
EloraTZP
Obesity / Type 2 diabetes
Phase 3
Phase 3 initiation · Q4 202623.3% weight loss at 48 weeks versus 14.8% for tirzepatide 15 mg in type 2 diabetes
Ebglyss (lebrikizumab)
Atopic dermatitis
Commercial
Commercial expansion and operating leverage
Jaypirca (pirtobrutinib)
B-cell malignancies
Commercial
Commercial expansion and lifecycle development
Kisunla (donanemab)
Early symptomatic Alzheimer's disease
Commercial
Commercial adoption, reimbursement expansion and diagnostic-infrastructure evolution
Remternetug
Alzheimer's disease
Phase 3
Clinical development updates
04 / Connected research

Published on LLY

View full archive
  1. 01

    Eli Lilly’s Eloralintide + Tirzepatide: Stronger Parts, Not Synergy in Diabetes

    Lilly’s 10-arm eloralintide + tirzepatide Phase 2 in type 2 diabetes reads out at EASD. Our bar: 12–14% placebo-adj. weight loss at go-forward dose; <11% disappoints. GI burden decides market.

    Read
  2. 02

    GLP-1s Solved Efficacy. They Haven't Solved Obesity

    The two-leak problem in the obesity treatment funnel — and what oral drugs can and cannot fix.

    Read
  3. 03

    Retatrutide’s 28%: The PCSK9 Mistake

    Why Superior Efficacy Doesn't Always Win the Market

    Read
  4. 04

    Obesity: Leaders De-risked, Debate Shifting Toward Market Structure

    Obesity Is Evolving From a Drug Category Into Metabolic Infrastructure

    Read